Chugai Pharmaceuticals Builds Yokohama R&D Center

Published 6-5-2019

Chugai Pharmaceuticals will begin construction in August of 2019 on a $1.15 billion research and development center in Yokohama, Japan. Consolidating two labs currently sited in Gotemba and Kamakura, the facility will support drug discovery including the creation of therapies based on next-generation antibodies and synthetic macrocycles, also known as middle molecules. The pharmaceutical research center will leverage leading-edge automation processes and artificial intelligence technologies to accelerate the delivery of innovative medicines to patients worldwide. Completion is expected in August of 2022 with operations commencing in January of 2023.